IBRX
ImmunityBio, Inc.
There isn't enough reported data to score IBRX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
IBRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
IBRX's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
IBRX PE Valuation
IBRX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
IBRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IBRX's losses to grow, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
IBRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.08 | -$0.68 |
| Q2 2026 | -$0.97 | -$0.50 |
| Q1 2026 | -$0.85 | -$0.28 |
| Q4 2025 | -$0.38 | +$0.24 |
| Q3 2025 | -$0.40 | +$0.51 |
| Q2 2025 | -$0.47 | +$0.49 |
| Q1 2025 | -$0.57 | +$0.51 |
| Q4 2024 | -$0.62 | +$0.53 |
IBRX lost $1.08 per share over the past year, and its loss has widened in each of the last three quarters.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over IBRX on earnings quality, reporting a profit while its opponent remains loss making.
IBRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $48.8M | +52% |
| Q2 2026 | $51.2M | +94% |
| Q1 2026 | $44.2M | +168% |
| Q4 2025 | $38.3M | +407% |
| Q3 2025 | $32.1M | +425% |
| Q2 2025 | $26.4M | +2424% |
| Q1 2025 | $16.5M | +41193% |
| Q4 2024 | $7.6M | +5333% |
IBRX has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -160% | +14 points |
| Q2 2026 | -120% | +149 points |
| Q1 2026 | -158% | +232 points |
| Q4 2025 | -169% | +750 points |
| Q3 2025 | -174% | +1141 points |
| Q2 2025 | -270% | +9218 points |
| Q1 2025 | -390% | +237600 points |
| Q4 2024 | -919% | +60512 points |
IBRX's operating margin was −160% last quarter, up 14 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over IBRX on profitability, with a higher operating margin.
IBRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$78.3M | -$8.6M |
| Q2 2026 | -$70M | +$10.8M |
| Q1 2026 | -$77.1M | +$9.9M |
| Q4 2025 | -$71.3M | +$16M |
| Q3 2025 | -$69.6M | +$31.9M |
| Q2 2025 | -$80.8M | +$20.2M |
| Q1 2025 | -$87M | +$21.2M |
| Q4 2024 | -$87.3M | +$36M |
IBRX has burned cash in almost every quarter: −$297M over the past year, against −$325M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over IBRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IBRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +10.9M shares |
| 1 year | +12% | +114M shares |
| 3 years | +143% | +623M shares |
| 5 years | +176% | +676M shares |
| Available history | +978% | +963M shares |
IBRX has 1.1B diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over IBRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
IBRX Net Leverage
IBRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
IBRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 29.3 | Neutral |
IBRX's weekly RSI is 39 (neutral) and its Stochastic is 29 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
IBRX PE vs Healthcare Sector
IBRX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
IBRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.70 | 30% below |
| 20 week MA | $8.24 | 26% below |
| 50 week MA | $7.15 | 15% below |
| 100 week MA | $4.93 | 23% above |
| 200 week MA | $4.42 | 37% above |
IBRX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over IBRX on trend strength, trading above more of its moving averages.
IBRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.74 | $16.0 | +328% |
| 2021 | $16.0 | $7.15 | -55% |
| 2022 | $7.15 | $5.46 | -24% |
| 2023 | $5.46 | $5.02 | -8.1% |
| 2024 | $5.02 | $2.78 | -45% |
| 2025 | $2.78 | $2.14 | -23% |
| 2026 YTD | $2.14 | $6.07 | +184% |
IBRX has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.